نمایش مختصر رکورد

dc.contributor.authorGholami, Amiren_US
dc.contributor.authorMousavie Anijdan, Seyyed Hosseinen_US
dc.date.accessioned1399-07-09T08:24:58Zfa_IR
dc.date.accessioned2020-09-30T08:24:58Z
dc.date.available1399-07-09T08:24:58Zfa_IR
dc.date.available2020-09-30T08:24:58Z
dc.date.issued2016-10-01en_US
dc.date.issued1395-07-10fa_IR
dc.date.submitted2016-10-23en_US
dc.date.submitted1395-08-02fa_IR
dc.identifier.citationGholami, Amir, Mousavie Anijdan, Seyyed Hossein. (2016). Development of 153Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI. Iranian Journal of Basic Medical Sciences, 19(10), 1056-1062. doi: 10.22038/ijbms.2016.7730en_US
dc.identifier.issn2008-3866
dc.identifier.issn2008-3874
dc.identifier.urihttps://dx.doi.org/10.22038/ijbms.2016.7730
dc.identifier.urihttp://ijbms.mums.ac.ir/article_7730.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/340978
dc.description.abstract<strong><em>Objective(s)</em></strong>: This study describes the preparation, biodistribution of <sup>153</sup>Sm-DTPA-SPION after intravenous injection in rats. <strong><em>Materials and Methods:</em></strong> The chelator DTPA dianhydride was conjugated to SPION using a small modification of the well-known cyclic anhydride method. Conjugation was done at a 1: 4 (SPION: ccDTPA) molar ratio. Conjugation reaction was purified with magnetic assorting column (MACs) using high gradient magnetic field following incubation, the radio labeled conjugate was checked using RTLC method for labeling and purity checked. <strong><em>Results: </em></strong>The RTLC showed that labeling yield was above 99% after purification and the compound have good <em>in vitro</em> stabilities until 48 hr post injection in the presence of human serum. The biodistribution of <sup>153</sup>Sm-DTPA-SPION in rats showed dramatic uptake in the reticuloendothelial system (RES) and their clearance is so fast in other organs especially in the blood. Biodistribution results show that after 30 min post injection more than 84% of injected activities were taken up by the liver and spleen (about 64% and 20%, respectively). <strong><em>Conclusion:</em></strong> Due to magnificent uptakes of this radiotracer in the liver and spleen and their fast clearance from other tissues, especially in blood, it is suggested that this radiotracer would be a potential candidate for RES theranostic purposes.en_US
dc.format.extent1359
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_US
dc.publisherMashhad University of Medical Sciencesen_US
dc.relation.ispartofIranian Journal of Basic Medical Sciencesen_US
dc.relation.isversionofhttps://dx.doi.org/10.22038/ijbms.2016.7730
dc.subjectBiodistributionen_US
dc.subjectLiveren_US
dc.subjectMulti-modality imagingen_US
dc.subjectSuper paramagnetic iron - oxide nanoparticlesen_US
dc.subjectTheranosticen_US
dc.subject153Smen_US
dc.titleDevelopment of 153Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRIen_US
dc.typeTexten_US
dc.typeOriginal Articleen_US
dc.contributor.departmentDepartment of Nuclear Medicine, Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, Iranen_US
dc.contributor.departmentDepartment of Radiation Technology, Allied Medicine Faculty, Babol University of Medical Sciences, Babol, Iranen_US
dc.citation.volume19
dc.citation.issue10
dc.citation.spage1056
dc.citation.epage1062


فایل‌های این مورد

Thumbnail

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد